OtherTheranostics
Open Access
Theranostics targeting fibroblast activation protein in the tumor stroma: 64Cu and 225Ac labelled FAPI-04 in pancreatic cancer xenograft mouse models
Tadashi Watabe, Yuwei Liu, Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Thomas Lindner, Kazuhiro Ooe, Atsushi Toyoshima, Kojiro Nagata, Eku Shimosegawa, Uwe Haberkorn, Clemens Kratochwil, Atsushi Shinohara, Frederik Giesel and Jun Hatazawa
Journal of Nuclear Medicine October 2019, jnumed.119.233122; DOI: https://doi.org/10.2967/jnumed.119.233122
Tadashi Watabe
1 Graduate School of Medicine, Osaka University, Japan;
Yuwei Liu
1 Graduate School of Medicine, Osaka University, Japan;
Kazuko Kaneda-Nakashima
2 Institute for Radiation Sciences, Osaka University;
Yoshifumi Shirakami
2 Institute for Radiation Sciences, Osaka University;
Thomas Lindner
3 University Hospital Heidelberg, Germany;
Kazuhiro Ooe
1 Graduate School of Medicine, Osaka University, Japan;
Atsushi Toyoshima
2 Institute for Radiation Sciences, Osaka University;
Kojiro Nagata
2 Institute for Radiation Sciences, Osaka University;
Eku Shimosegawa
1 Graduate School of Medicine, Osaka University, Japan;
Uwe Haberkorn
3 University Hospital Heidelberg, Germany;
Clemens Kratochwil
3 University Hospital Heidelberg, Germany;
Atsushi Shinohara
4 Graduate School of Science, Osaka University;
Frederik Giesel
3 University Hospital Heidelberg, Germany;
Jun Hatazawa
5 Research Center for Nuclear Physics, Osaka University, Japan
Article Figures & Data
Additional Files
Supplemental Data
Files in this Data Supplement:
In this issue
Journal of Nuclear Medicine
Vol. 65, Issue 4
April 1, 2024
Theranostics targeting fibroblast activation protein in the tumor stroma: 64Cu and 225Ac labelled FAPI-04 in pancreatic cancer xenograft mouse models
Tadashi Watabe, Yuwei Liu, Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Thomas Lindner, Kazuhiro Ooe, Atsushi Toyoshima, Kojiro Nagata, Eku Shimosegawa, Uwe Haberkorn, Clemens Kratochwil, Atsushi Shinohara, Frederik Giesel, Jun Hatazawa
Journal of Nuclear Medicine Oct 2019, jnumed.119.233122; DOI: 10.2967/jnumed.119.233122
Theranostics targeting fibroblast activation protein in the tumor stroma: 64Cu and 225Ac labelled FAPI-04 in pancreatic cancer xenograft mouse models
Tadashi Watabe, Yuwei Liu, Kazuko Kaneda-Nakashima, Yoshifumi Shirakami, Thomas Lindner, Kazuhiro Ooe, Atsushi Toyoshima, Kojiro Nagata, Eku Shimosegawa, Uwe Haberkorn, Clemens Kratochwil, Atsushi Shinohara, Frederik Giesel, Jun Hatazawa
Journal of Nuclear Medicine Oct 2019, jnumed.119.233122; DOI: 10.2967/jnumed.119.233122
Jump to section
Related Articles
Cited By...
- Fibroblast Activation Protein Inhibitor-Based Radionuclide Therapies: Current Status and Future Directions
- Clinical Translation of Targeted {alpha}-Therapy: An Evolution or a Revolution?
- Fibroblast Activation Protein-Targeted Radioligand Therapy for Treatment of Solid Tumors
- Clinical Translation of Targeted {alpha}-Therapy: An Evolution or a Revolution?
- Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of 68Ga-Labeled FAPI Dimer
- Albumin Binder-Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy
- Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results
- Eliminating fibroblast activation protein-{alpha} expressing cells by photoimmunotheranostics
- FAPI PET/CT: Will It End the Hegemony of 18F-FDG in Oncology?
- The Latest Developments in Imaging of Fibroblast Activation Protein
- Three Distinct Stroma Types in Human Pancreatic Cancer Identified by Image Analysis of Fibroblast Subpopulations and Collagen
- Targeting Fibroblast Activation Protein: Radiosynthesis and Preclinical Evaluation of an 18F-Labeled FAP Inhibitor